GeneNews Limited announced that a poster describing a 786-cohort study entitled "Blood RNA Biomarker Detects Both Left- and Right-sided Colorectal Neoplasms" has been accepted for presentation at the Next Generation Dx Summit in Washington, DC August 24 to 26.
The poster reports on the application of a seven gene biomarker panel to 377 colorectal cancer ("CRC") patients and 409 controls. This seven gene biomarker panel forms the basis of the company’s lead product, ColonSentry™, the world’s first blood test to assess an individual’s current risk for colorectal cancer. The poster concludes that the biomarker panel was able to detect right-sided CRC lesions across all stages with a sensitivity that is at least equal to the detection observed for left-sided lesions.
"Colonoscopy is widely regarded as the gold standard for colorectal cancer detection. Recent studies, however, suggest that its effectiveness is mostly confined to detection of tumors on the left side of the colon, with poor detection of right-sided lesions. Routine use of a blood test that can detect both left-sided and right-sided lesions could increase the effectiveness of colorectal cancer screening by revealing the potential presence of neoplasms in advance of colonoscopy," said Dr. Robert Burakoff, one of the investigators for the reported study, Clinical Chief of Gastroenterology and Director of the Center for Digestive Diseases and of the Crohn’s and Colitis Center at Brigham and Women’s Hospital, Harvard Medical School.
"We have long believed that widespread adoption ColonSentry™ would encourage more patients to engage in colorectal cancer screening, leading to earlier detection, improved patient outcomes and reduced healthcare costs. The results from this study further demonstrate the value of using ColonSentry™ as a routine test in advance of colonoscopy to provide a pre-screening alert, ultimately leading to enhanced colorectal cancer screening effectiveness," said Gailina J. Liew, President & Chief Operating Officer of GeneNews.